• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 4:47:59 PM ET
    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $HSKA alert in real time by email
    SC 13G 1 d118567dsc13g.htm HESKA CORP. Heska Corp.

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.    )*

     

     

    Heska Corp.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    42805E306

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 42805E306

     

    1.     

    Names of Reporting Persons

     

    Alger Associates, Inc. 13-3017981

    2.     

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☐

     

    3.     

    SEC Use Only

     

    4.     

    Citizenship or Place of Organization

     

    New York

    Number of  

    Shares

     Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       5.       

    Sole Voting Power

     

    1,197,758

       6.       

    Shared Voting Power

     

    0

       7.       

    Sole Dispositive Power

     

    1,197,758

       8.       

    Shared Dispositive Power

     

    0

      9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,197,758

    10.     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.     

    Percent of Class Represented by Amount in Row (9)

     

    12.67%

    12.     

    Type of Reporting Person (See Instructions)

     

    HC

     

    2


    CUSIP No. 42805E306

     

    1.     

    Names of Reporting Persons

     

    Alger Group Holdings, LLC

    2.     

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☐

     

    3.     

    SEC Use Only

     

    4.     

    Citizenship or Place of Organization

     

    Delaware

    Number of  

    Shares

     Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       5.       

    Sole Voting Power

     

    1,197,758

       6.       

    Shared Voting Power

     

    0

       7.       

    Sole Dispositive Power

     

    1,197,758

       8.       

    Shared Dispositive Power

     

    0

      9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,197,758

    10.     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.     

    Percent of Class Represented by Amount in Row (9)

     

    12.67%

    12.     

    Type of Reporting Person (See Instructions)

     

    HC

     

    3


    CUSIP No. 42805E306

     

    1.     

    Names of Reporting Persons

     

    Fred Alger Management, LLC

    2.     

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐        (b) ☐

     

    3.     

    SEC Use Only

     

    4.     

    Citizenship or Place of Organization

     

    Delaware

    Number of  

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       5.       

    Sole Voting Power

     

    1,197,758

       6.       

    Shared Voting Power

     

    0

       7.       

    Sole Dispositive Power

     

    1,197,758

       8.       

    Shared Dispositive Power

     

    0

      9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,197,758

    10.     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.     

    Percent of Class Represented by Amount in Row (9)

     

    12.67%

    12.     

    Type of Reporting Person (See Instructions)

     

    IA

     

    4


    Item 1.          
      (a)    Name of Issuer
        

    Heska Corp.

      (b)   
        

    Address of Issuer’s Principal Executive Offices

    1613 Prospect Parkway

    Fort Collins, CO 80525

    Item 2.          
      (a)    Name of Person Filing
         Alger Associates, Inc
         Alger Group Holdings, LLC
        

    Fred Alger Management, LLC

      (b)    Address of Principal Business Office or, if none, Residence
        

    360 Park Avenue South, New York, NY 10010

      (c)    Citizenship
         Alger Associates, Inc. – New York
         Alger Group Holdings, LLC – Delaware
        

    Fred Alger Management, LLC – Delaware

      (d)    Title of Class of Securities
        

    Common Stock

      (e)    CUSIP Number
        

    42805E306

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a)    ☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b)    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c)    ☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d)    ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e)    ☐   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)    ☐   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      (g)    ☒   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      (h)    ☐   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i)    ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j)    ☐   A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
      (k)    ☐   Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with§ 240.13d–1(b)(1)(ii)(J), please specify the type of institution:                                     

     

    5


    Item 4.   Ownership   
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a)     Amount beneficially owned:
       

    1,197,758

      (b)   Percent of class:
       

    12.67%

      (c)   Number of shares as to which the person has:
       

     

        (i)   Sole power to vote or to direct the vote
         

    1,197,758

        (ii)   Shared power to vote or to direct the vote
         

    0

          (iii)     Sole power to dispose or to direct the disposition of
         

    1,197,758

        (iv)   Shared power to dispose or to direct the disposition of
         

    0

     

    Item 5.   Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6.   Ownership of More than Five Percent on Behalf of Another Person
    The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC, (“FAM”) is a registered investment adviser. FAM is a 100% owned subsidiary of Alger Group Holdings, LLC (“AGH”), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company.
    Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    See Exhibit A
    Item 8.   Identification and Classification of Members of the Group
    Item 9.   Notice of Dissolution of Group
    Item 10.   Certification

     

    6


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    By: Alger Associates, Inc.
    By:  

    /s/ Hal Liebes

    Name:   Hal Liebes
    Title:   Secretary
    Date:   February 16, 2021
    By: Alger Group Holdings, LLC
    By:  

    /s/ Hal Liebes

    Name:   Hal Liebes
    Title:   Secretary
    Date:   February 16, 2021
    By: Fred Alger Management, LLC
    By:  

    /s/ Tina Payne

    Name:   Tina Payne
    Title:   Senior Vice President
    Date:   February 16, 2021

     

    7


    Exhibit A

    Pursuant to Item 7 of this schedule, the following lists the identity and item 3 classification of each entity that directly beneficially owns shares of the security class being reported.

    Fred Alger Management, LLC — IA


    Joint Filing Agreement

    The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Heska Corp. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.

     

    By: Alger Associates, Inc.
    By:  

    /s/ Hal Liebes

    Name:   Hal Liebes
    Title:   Secretary
    Date:   February 16, 2021
    By: Alger Group Holdings, LLC
    By:  

    /s/ Hal Liebes

    Name:   Hal Liebes
    Title:   Secretary
    Date:   February 16, 2021
    By: Fred Alger Management, LLC
    By:  

    /s/ Tina Payne

    Name:   Tina Payne
    Title:   Senior Vice President
    Date:   February 16, 2021
    Get the next $HSKA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSKA

    DatePrice TargetRatingAnalyst
    1/6/2023$58.00Equal-Weight → Underweight
    Morgan Stanley
    3/1/2022$190.00 → $161.00Equal-Weight
    Morgan Stanley
    2/23/2022$300.00 → $250.00Overweight
    JP Morgan
    1/6/2022$210.00Overweight
    Piper Sandler
    11/18/2021$190.00Equal-Weight
    Morgan Stanley
    8/4/2021$240.00 → $305.00Overweight
    Piper Sandler
    7/12/2021$280.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $HSKA
    Financials

    Live finance-specific insights

    See more
    • Heska Corporation Reports Fourth Quarter and Full Year 2022 Results

      Full Year Sales $257.3 Million, Full Year Gross Margin Up 150 Basis Points to 43.2% Full Year North America Lab Consumables Sales Up 8.7%, Total Active Subscriptions Up 18% LOVELAND, Colo., Feb. 28, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2022. Fourth Quarter and Full Year 2022 and Year Over Year ("YOY") Metrics $ in mi

      2/28/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Heska Fourth Quarter and Full Year 2022 Financial Results and Earnings Call Scheduled for February 28, 2023

      LOVELAND, Colo., Feb. 8, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its fourth quarter and full year 2022 financial performance in a press release before the market opens on Tuesday, February 28, 2023. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-877-41-6152From outside of the United States, please dial 1-201-389-

      2/8/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Heska Corporation Completes Acquisition of LightDeck Diagnostics

      LOVELAND, Colo., Jan. 3, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of acquisition of 100% of the shares of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the "Acquisition").  The Acquisition, which was first announced on September 12, 2022, represent

      1/3/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Heska Corp downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Heska Corp from Equal-Weight to Underweight and set a new price target of $58.00

      1/6/23 8:09:57 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Morgan Stanley reiterated coverage on Heska with a new price target

      Morgan Stanley reiterated coverage of Heska with a rating of Equal-Weight and set a new price target of $161.00 from $190.00 previously

      3/1/22 9:56:21 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • JP Morgan reiterated coverage on Heska with a new price target

      JP Morgan reiterated coverage of Heska with a rating of Overweight and set a new price target of $250.00 from $300.00 previously

      2/23/22 8:14:03 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bee Vaccine Pioneer Dalan Secures $4.5M to Fuel Global Expansion and Product Development

      Key Points: $4.5 million in Series Seed 3 funding, led by Prime Movers Lab with participation from At One Ventures, bringing the company's total funding to $10 million. The funding will accelerate Dalan's product pipeline and facilitate its global expansion, aiming to protect the health of honeybees and secure the global food supply. Dalan Animal Health, Inc. ("Dalan"), a pioneering biotech company in insect health, today announced the successful closure of a $4.5 million Series Seed 3 funding round. The round was led by Prime Movers Lab with participation from At One Ventures, bringing Dalan's total funding to $10 million. The additional funding will enable Dalan to expedite its

      6/27/23 9:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • eXp World Holdings & Privia Health Group Set to Join S&P SmallCap 600

      NEW YORK, June 7, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 14: eXp World Holdings Inc. (NASD: EXPI) will replace Heska Corp. (NASD: HSKA). Mars Inc. is acquiring Heska in a deal expected to be completed soon pending final conditions.Privia Health Group Inc. (NASD: PRVA) will replace Ruth's Hospitality Group Inc. (NASD: RUTH). S&P 500 constituent Darden Restaurants Inc. (NYSE:DRI) is acquiring Ruth's Hospitality Group in a deal expected to be completed soon pending final conditions.Following is a summary of the changes that will take place prior to the open of trading on the

      6/7/23 6:37:00 PM ET
      $DRI
      $EXPI
      $HSKA
      $PRVA
      Restaurants
      Consumer Discretionary
      Real Estate
      Finance
    • Dalan Animal Health Ships First Honey Bee Vaccine to Tauzer Apiaries, Potentially Protecting 25 Million Bees.

      Dalan Animal Health, Inc. ("Dalan"), the biotech company pioneering insect health with the world's first honey bee vaccine, is proud to announce its first product shipment to a commercial beekeeper. The shipment is for Trevor Tauzer of Tauzer Apiaries in California and contains 500 doses, potentially protecting 25 million bees at an average of 50,000 bees per hive. This milestone follows the U.S. Department of Agriculture (USDA) granting a conditional license to Dalan's first-in-class honeybee vaccine earlier this year. The vaccine is indicated to protect honeybees against the devastating American Foulbrood disease caused by the bacteria Paenibacillus larvae. Honeybees are a critical co

      5/23/23 7:20:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      4/10/23 2:50:12 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      2/14/23 4:07:17 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      2/10/23 10:12:43 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    SEC Filings

    See more

    $HSKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 15-12G filed by Heska Corporation

      15-12G - HESKA CORP (0001038133) (Filer)

      6/23/23 6:01:38 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Heska Corporation

      EFFECT - HESKA CORP (0001038133) (Filer)

      6/14/23 12:15:09 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Heska Corporation

      EFFECT - HESKA CORP (0001038133) (Filer)

      6/14/23 12:15:13 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Maples Sharon J.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:54 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Eyl Steven M.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:55 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Hasenmaier Joachim A.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:56 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Leadership Updates

    Live Leadership Updates

    See more
    • Heska Corporation Elects Dr. Joachim Hasenmaier to Board of Directors

      LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. Joachim Hasenmaier, the former head of Boehringer Ingelheim Animal Health, to the Company's Board of Directors, effective January 11, 2021. Dr. Joachim Hasenmaier most recently served as a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer healthcare businesses. Previously, as head of animal health of Boehringer Ingelheim, Dr. Hasenmaier led the rapid growth and expansion

      1/12/21 4:30:00 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care